Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01995188
Recruitment Status : Completed
First Posted : November 26, 2013
Last Update Posted : October 4, 2017
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Tracking Information
First Submitted Date  ICMJE November 15, 2013
First Posted Date  ICMJE November 26, 2013
Last Update Posted Date October 4, 2017
Actual Study Start Date  ICMJE December 16, 2013
Actual Primary Completion Date November 9, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 13, 2016)
  • Number of Participants with Dose-limiting Toxicities (DLTs) [ Time Frame: 21 days ]
  • Number of Participants with Adverse events (AE) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 until 30 days after the last-infusion (up to approximately 3 years) ]
  • Number of Participants with Anti-DNIB0600A Antibodies [ Time Frame: Pre-infusion (0 hour) at Day 1 of Cycle 1, 2, 3, 4 (each cycle of 21 days), 30 days after last infusion (up to approximately 3 years) ]
Original Primary Outcome Measures  ICMJE
 (submitted: November 21, 2013)
  • Incidence of dose-limiting toxicities (DLTs) [ Time Frame: 21 days ]
  • Incidence of adverse events (AE) [ Time Frame: Approximately 6 months ]
  • Incidence of anti-DNIB0600A antibodies [ Time Frame: 1 year ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 13, 2016)
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] of DNIB0600A [ Time Frame: Pre-infusion (0 hour), hour 0.5,1 post-infusion Cycle 1 (each cycle= 28 days); 7, 14 days post-infusion of Cycle 1 (Day 8, 15 respectively); Day 1 of Cycle 2 and subsequent cycles up to last dose; 30 days after last dose (up to approximately 3 years) ]
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Pre-infusion (0 hour), hour 0.5,1 post-infusion Cycle 1 (each cycle= 28 days); 7, 14 days post-infusion of Cycle 1 (Day 8, 15 respectively); Day 1 of Cycle 2 and subsequent cycles up to last dose; 30 days after last dose (up to approximately 3 years) ]
  • Minimum Observed Plasma Trough Concentration (Cmin) [ Time Frame: Pre-infusion (0 hour), hour 0.5,1 post-infusion Cycle 1 (each cycle= 28 days); 7, 14 days post-infusion of Cycle 1 (Day 8, 15 respectively); Day 1 of Cycle 2 and subsequent cycles up to last dose; 30 days after last dose (up to approximately 3 years) ]
  • Systemic Clearance (CL) [ Time Frame: Pre-infusion (0 hour), hour 0.5,1 post-infusion Cycle 1 (each cycle= 28 days); 7, 14 days post-infusion of Cycle 1 (Day 8, 15 respectively); Day 1 of Cycle 2 and subsequent cycles up to last dose; 30 days after last dose (up to approximately 3 years) ]
  • Volume of Distribution at Steady State (Vss) [ Time Frame: Pre-infusion (0 hour), hour 0.5,1 post-infusion Cycle 1 (each cycle= 28 days); 7, 14 days post-infusion of Cycle 1 (Day 8, 15 respectively); Day 1 of Cycle 2 and subsequent cycles up to last dose; 30 days after last dose (up to approximately 3 years) ]
  • Plasma Decay Half-Life (t1/2) [ Time Frame: Pre-infusion (0 hour), hour 0.5,1 post-infusion Cycle 1 (each cycle= 28 days); 7, 14 days post-infusion of Cycle 1 (Day 8, 15 respectively); Day 1 of Cycle 2 and subsequent cycles up to last dose; 30 days after last dose (up to approximately 3 years) ]
  • Percentage of Participants With Objective Response as Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) [ Time Frame: From screening thereafter every 2 cycles (from Cycle 2 to Cycle 16) or every 4 cycles (from Cycle 10) until disease progression or death (up to approximately 3 years) ]
  • Duration of Objective Response Rate as Assessed by RECIST v1.1 [ Time Frame: From screening thereafter every 2 cycles (from Cycle 2 to Cycle 16) or every 4 cycles (from Cycle 10) until disease progression or death (up to approximately 3 years) ]
  • Progression Free Survival (PFS) as Assessed by RECIST v1.1 [ Time Frame: Day 1 to the first occurrence of disease progression or death within 30 days of the last administration of study drug, whichever occurs first (up to approximately 3 years) ]
Original Secondary Outcome Measures  ICMJE
 (submitted: November 21, 2013)
  • Area under the concentration-time curve (AUC) of DNIB0600A [ Time Frame: 1 year ]
  • Objective response determined by Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: More than 4 weeks after baseline evaluation ]
  • Progression-free survival [ Time Frame: Approximately 6 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Official Title  ICMJE A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
Brief Summary This open-label, multicenter, phase 1b study will evaluate the safety and pharmacokinetics of DNIB0600A in participants with platinum-sensitive ovarian cancer (PSOC) or Non-Squamous Non-small Cell Lung Cancer (NSCLC). The maximum tolerated dose of intravenously infused DNIB0600A in combination with carboplatin will be determined in escalating dose cohorts. The combination of DNIB0600A and carboplatin will then be evaluated with and without bevacizumab [Avastin] in three dose expansion cohorts.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non-Squamous Non-Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Bevacizumab
    Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
    Other Name: Avastin
  • Drug: Carboplatin
    Carboplatin fixed dose of AUC=6 mg/mL*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
  • Drug: DNIB0600A
    DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
Study Arms  ICMJE
  • Experimental: Dose Escalation Cohort: DNIB0600A+Carboplatin
    DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
    Interventions:
    • Drug: Carboplatin
    • Drug: DNIB0600A
  • Experimental: NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin
    Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
    Intervention: Drug: DNIB0600A
  • Experimental: PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin
    RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
    Interventions:
    • Drug: Carboplatin
    • Drug: DNIB0600A
  • Experimental: PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab
    RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
    Interventions:
    • Drug: Bevacizumab
    • Drug: Carboplatin
    • Drug: DNIB0600A
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 2, 2017)
41
Original Estimated Enrollment  ICMJE
 (submitted: November 21, 2013)
42
Actual Study Completion Date  ICMJE November 9, 2016
Actual Primary Completion Date November 9, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.
  • Histologically documented epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that is platinum sensitive.
  • PSOC (i.e., epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) with documented radiographic progression or relapse within 6 to 18 months of most recent platinum-based chemotherapy.
  • Female participants of childbearing potential must use effective contraception as defined by study protocol and cannot be pregnant or breastfeeding.

NSCLC-specific Inclusion Criteria:

  • Histological documentation of incurable, locally advanced, or metastatic non-squamous
  • NSCLC that has progressed on prior treatment
  • Not more than 2 prior regimens in the metastatic setting, including one prior cytotoxic regimen and one prior non-cytotoxic regimen (prior treatment with adjuvant therapy within 6 months of recurrence is considered a treatment regimen in the metastatic setting).
  • For participants with a documented epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement, one additional line of non-cytotoxic prior treatment will be permitted provided the therapy is a targeted agent against the EGFR mutation or ALK rearrangement.
  • For participants with lung cancer, centrally confirmed high expression of a sodium-dependent phosphate transporter (NaPi2b) by immunohistochemistry (IHC) is required (i.e., IHC 2+ or 3+).

Exclusion Criteria:

  • Anti-tumor therapy of any kind or major surgery within 4 weeks prior to Day 1.
  • For ovarian cancer participants only, platinum-based chemotherapy within 6 months prior to Day 1.
  • For ovarian cancer participants only, platinum treatment with more than two platinum-based chemotherapy regiments or more than four anti-cancer regimens, overall, for the treatment of ovarian cancer.
  • Palliative radiation within 2 weeks prior to Day 1.
  • Toxicity (except alopecia and anorexia) from prior therapy or neuropathy of grades > 1.
  • Evidence of any significant disease or condition that could affect compliance with the protocol or interpretation of results.
  • Known active infection (except fungal nail infections).
  • History of liver disease or human immunodeficiency virus (HIV).
  • Other malignancy within the last 5 years, except for adequately treated or controlled carcinoma in situ of the cervix or skin cancer or primary endometrial cancer of stage </= 1B.
  • Untreated or active central nervous system (CNS) metastases.
  • Prior treatment with NaPi2b- targeted therapy.

Bevacizumab-Specific Exclusion Criteria (for Participants in Second Ovarian

Expansion Cohort Only):

  • Inadequately controlled hypertension or history of hypertensive crisis or encephalopathy.
  • History of heart problems or thrombosis within 6 months prior to study start.
  • History of stroke within 6 months prior to study enrollment.
  • History of significant vascular disease.
  • History of expectoration of blood within 1 month prior to study start or blood clotting problems.
  • Core biopsy or other minor surgical procedure within 7 days prior to study start
  • Serious and non-healing wound, active ulcer, or untreated bone fracture.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01995188
Other Study ID Numbers  ICMJE GO29006
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Genentech, Inc.
Study Sponsor  ICMJE Genentech, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Genentech, Inc.
PRS Account Genentech, Inc.
Verification Date October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP